MNKD – mannkind corporation (US:NASDAQ)
Stock Stats
News
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion [Seeking Alpha]
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration [Globe and Mail, The (Toronto, Canada)]
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets [Globe and Mail, The (Toronto, Canada)]
Form 4 MANNKIND CORP For: Jan 08 Filed by: Tross Stuart A
Form 144 MANNKIND CORP Filed by: Tross Stuart A
Form 4 MANNKIND CORP For: Dec 24 Filed by: Castagna Michael
Form 4 MANNKIND CORP For: Dec 17 Filed by: Castagna Michael
Form 4 MANNKIND CORP For: Dec 12 Filed by: Castagna Michael
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.